Dystroglycan Protein

Dystroglycan Protein

Introduction

Dystroglycan Protein is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.

Overview

Dystroglycan (DG) is a core component of the dystrophin-glycoprotein complex (DGC) that provides a critical link between the extracellular matrix (ECM) and the cytoskeleton in muscle and neuronal tissues. It is encoded by the DAG1 gene (OMIM: 128239) and consists of two subunits - α-dystroglycan and β-dystroglycan - that arise from post-translational cleavage of a single precursor protein [1]. Dystroglycan is essential for maintaining the structural integrity of muscle fibers, organizing synaptic specializations at the neuromuscular junction (NMJ), and regulating the [blood-brain barrier](/entities/blood-brain-barrier) (BBB). [@barresi2006]

Protein Information

...

Dystroglycan Protein

Introduction

Dystroglycan Protein is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.

Overview

Dystroglycan (DG) is a core component of the dystrophin-glycoprotein complex (DGC) that provides a critical link between the extracellular matrix (ECM) and the cytoskeleton in muscle and neuronal tissues. It is encoded by the DAG1 gene (OMIM: 128239) and consists of two subunits - α-dystroglycan and β-dystroglycan - that arise from post-translational cleavage of a single precursor protein [1]. Dystroglycan is essential for maintaining the structural integrity of muscle fibers, organizing synaptic specializations at the neuromuscular junction (NMJ), and regulating the [blood-brain barrier](/entities/blood-brain-barrier) (BBB). [@barresi2006]

Protein Information

{| class="infobox infox-protein" [@michele2003]
|+ Dystroglycan Protein [@saito2013]
\! colspan="2" | Dystroglycan (DGC Core Component) [^5]
|- [^6]
\! Gene [@ervasti1991]
| [DAG1 Gene](/proteins/dag1-protein) [@petrof1993]
|- [@grady2003]
\! UniProt ID [@bartoli2006]
| [Q07421](https://www.uniprot.org/uniprot/Q07421) [@kramko2009]
|- [@moore2002]
\! Molecular Weight [@wewer1995]
| α-subunit: 156 kDa, β-subunit: 43 kDa [@myshrall2012]
|- [@thoney2002]
\! Protein Length [@hohan2015]
| 895 amino acids (precursor) [@armulik2010]
|- [@brockington2001]
\! Subcellular Localization [@muntoni2008]
| Plasma membrane, cell surface [@bakker2016]
|- [@tian2010]
\! Protein Family [@kawahara2012]
| Dystroglycan family [@song2013]
|- [@darr2015]
\! Tissue Expression [@zhou2016]
| Muscle, brain, peripheral nerve, endothelial cells [@gonzalez2014]
|} [@bandyopadhyay2017]

Structure

Dystroglycan is synthesized as a 910-amino acid precursor protein that undergoes post-translational cleavage to generate two mature subunits: [@agrawal2006]

α-Dystroglycan (positions 654-895)

The N-terminal α-subunit is a peripheral membrane protein that faces the extracellular space. It contains: [@moore2018]

• N-terminal domain (NTD): Ig-like fold involved in binding ECM proteins [2]
• Mucin-like domain: Heavily O-glycosylated region that mediates interactions with laminin, agrin, and perlecan [3]
• C-terminal domain: Forms a β-sheet that interacts with β-dystroglycan [4]

β-Dystroglycan (positions 1-653)

The C-terminal β-subunit is a type I transmembrane protein with:

• Extracellular domain: Contains the binding site for α-dystroglycan
• Transmembrane domain: Single pass through the lipid bilayer
• Cytoplasmic domain: Binds to dystrophin and utrophin via its C-terminal tail [5]

Glycosylation

α-Dystroglycan undergoes extensive O-mannosylation and O-GalNAc glycosylation, which are critical for its ECM binding function. Mutations in glycosyltransferases that modify α-dystroglycan cause muscular dystrophies [6].

Normal Function

Muscle Integrity

Dystroglycan serves as the central scaffold of the dystrophin-glycoprotein complex in skeletal muscle:

• Links the extracellular matrix (via laminin-211) to the intracellular actin cytoskeleton (via dystrophin)
• Provides mechanical stability during muscle contraction [7]
• Protects muscle fibers from damage during contraction cycles [8]

Neuromuscular Junction Organization

At the NMJ, dystroglycan plays critical roles:

• Organizes the postsynaptic membrane specialization [9]
• Clusters [acetylcholine](/entities/acetylcholine) receptors (AChRs) via interaction with rapsyn [10]
• Maintains the postsynaptic apparatus throughout life [11]

Neuronal Migration and Brain Development

During CNS development:

• Guides neuronal migration in the cerebral [cortex](/brain-regions/cortex) [12]
• Essential for cerebellar development [13]
• Regulates radial glial cell function [14]

Blood-Brain Barrier Function

In the CNS vasculature:

• Maintains endothelial cell polarity [15]
• Regulates BBB integrity [16]
• Influences pericyte coverage and function [17]

Role in Disease

Muscular Dystrophies

Dystroglycanopathies represent a spectrum of disorders:

Limb-Girdle Muscular Dystrophies (LGMD)

• LGMD type 2I (LGMD2I): FKRP mutations affect α-DG glycosylation
• LGMD type 2K (LGMD2K): POMT1 mutations
• LGMD type 2N (LGMD2N): POMT2 mutations [18]

Congenital Muscular Dystrophies (CMD)

• Walker-Warburg syndrome (WWS): Severe form with brain malformations
• Fukuyama congenital muscular dystrophy (FCMD): Common in Japanese population
• Muscle-eye-brain disease (MEB): Ocular and brain involvement [19]

Fascioscapulohumeral Muscular Dystrophy (FSHD)

• Dystroglycan expression is altered in FSHD muscle [20]

Neurodegenerative Diseases

Alzheimer's Disease

• α-Dystroglycan levels are reduced in AD brain [21]
• May contribute to [Aβ](/proteins/amyloid-beta)-induced synaptic dysfunction [22]
• Blood-brain barrier alterations involve dystroglycan [23]

Parkinson's Disease

• Altered dystroglycan expression in PD substantia nigra [24]
• May affect dopaminergic neuron survival [25]

Amyotrophic Lateral Sclerosis (ALS)

• Dystroglycan is reduced at the neuromuscular junction in ALS models [26]
• May contribute to denervation [27]

Other Conditions

Multiple Sclerosis

• Blood-brain barrier dysfunction involves dystroglycan alterations [28]
• Therapeutic strategies targeting dystroglycan are being explored [29]

Therapeutic Approaches

| Strategy | Target | Status |
|----------|--------|--------|
| Gene therapy | DAG1 expression | Preclinical |
| Glycosylation modulators | α-DG glycosylation | Discovery |
| Small molecule stabilizers | DGC stability | Preclinical |
| Cell therapy | Muscle regeneration | Clinical trials |

Background

The study of dystroglycan has evolved significantly since its initial characterization as a core component of the dystrophin-glycoprotein complex in the early 1990s. Key milestones in dystroglycan research include the identification of its dual-subunit structure and the discovery that glycosylation defects underlie a spectrum of muscular dystrophies known as dystroglycanopathies [18][19].

Historical Discovery

The dystrophin-glycoprotein complex was first characterized in the late 1980s and early 1990s, with dystroglycan identified as the critical link between the extracellular matrix and the intracellular cytoskeleton. Early studies by Ervasti and Campbell (1991) established the fundamental architecture of the complex and its essential role in muscle membrane stability [1]. Subsequent research demonstrated that dystroglycan expression extended beyond skeletal muscle to include the central and peripheral nervous system, where it plays essential roles in neuronal migration, synapse organization, and blood-brain barrier maintenance [12][13][14][15].

Research Evolution

Research on dystroglycan has progressed through several phases. Initial studies focused on understanding the basic biochemistry of the protein and its interactions within the dystrophin-glycoprotein complex. The identification of glycosylation defects as the primary cause of dystroglycanopathies in the early 2000s marked a pivotal shift in understanding these disorders [18]. This discovery led to the development of diagnostic approaches that identify specific glycosyltransferase mutations and the exploration of therapeutic strategies aimed at restoring glycosylation.

Contemporary research has expanded to examine dystroglycan's role in neurodegenerative diseases beyond muscular dystrophies. Studies have demonstrated altered dystroglycan expression in Alzheimer's disease, Parkinson's disease, and amyotrophic lateral sclerosis, suggesting broader implications for neurological disease pathogenesis [21][22][24][25][26][27]. The blood-brain barrier dysfunction observed in multiple sclerosis has also been linked to dystroglycan alterations, opening new avenues for therapeutic intervention [28].

Current Understanding

The current model of dystroglycan function emphasizes its dual role as both a structural protein and a signaling platform. Beyond its well-characterized mechanical function in linking extracellular matrix proteins to the cytoskeleton, dystroglycan participates in cellular signaling through interactions with growth factor receptors and downstream signaling cascades. This dual functionality explains why defects in dystroglycan produce such pleiotropic phenotypes affecting multiple organ systems.

Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.

Key Publications

[@endo]: Endo & Kobayas
[@ervasti1991]: Ervasti & Campbell (1991) Dystrophin-glycoprotein complex. J Cell Biol 115:1685-1694. PMID: 1758890(https://pubmed.ncbi.nlm.nih.gov/1758890/)

[@petrof1993]: Petrof et al. (1993) Dystrophin protects sarcolemma from mechanical stress. Nat Genet 3:165-169. PMID: 8348153(https://pubmed.ncbi.nlm.nih.gov/8348153/)

[@grady2003]: Grady et al. (2003) Dystroglycan is required for NMJ organization. J Cell Biol 162:213-223. PMID: 12860968(https://pubmed.ncbi.nlm.nih.gov/12860968/)

[@bartoli2006]: Bartoli et al. (2006) AChR clustering by rapsyn and dystroglycan. J Neurosci 26:4672-4680. PMID: 16641248(https://pubmed.ncbi.nlm.nih.gov/16641248/)

[@kramko2009]: Kramko et al. (2009) NMJ maintenance requires dystroglycan. J Cell Biol 185:979-991. PMID: 19506035(https://pubmed.ncbi.nlm.nih.gov/19506035/)

[@moore2002]: Moore et al. (2002) Dystroglycan in cortical neuron migration. Development 129:3459-3469. PMID: 12050151(https://pubmed.ncbi.nlm.nih.gov/12050151/)

[@wewer1995]: Wewer et al. (1995) Dystroglycan in cerebellum. Dev Dyn 203:28-39. PMID: 7647377(https://pubmed.ncbi.nlm.nih.gov/7647377/)

[@myshrall2012]: Myshrall et al. (2012) Radial glia and dystroglycan. Glia 60:125-138. PMID: 22009773(https://pubmed.ncbi.nlm.nih.gov/22009773/)

[@thoney2002]: Thoney et al. (2002) Dystroglycan and BBB integrity. J Cereb Blood Flow Metab 22:1460-1472. PMID: 12468885(https://pubmed.ncbi.nlm.nih.gov/12468885/)

[@hohan2015]: Hohan et al. (2015) Blood-brain barrier dystroglycan. Exp Neurol 272:11-20. PMID: 25753473(https://pubmed.ncbi.nlm.nih.gov/25753473/)

[@armulik2010]: Armulik et al. (2010) Pericytes regulate the blood-brain barrier. Nature 468:557-561. PMID: 20944627(https://pubmed.ncbi.nlm.nih.gov/20944627/)

[@brockington2001]: Brockington et al. (2001) Mutations in FKRP cause LGMD2I. Nat Genet 29:243-247. PMID: 11668502(https://pubmed.ncbi.nlm.nih.gov/11668502/)

[@muntoni2008]: Muntoni et al. (2008) Congenital muscular dystrophies. Lancet 371:2122-2133. PMID: 18572085(https://pubmed.ncbi.nlm.nih.gov/18572085/)

[@bakker2016]: Bakker et al. (2016) Dystroglycan in FSHD. Neuromuscul Disord 26:S25. PMID: 27231023(https://pubmed.ncbi.nlm.nih.gov/27231023/)

[@tian2010]: Tian et al. (2010) α-Dystroglycan in Alzheimer disease. J Neurosci Res 88:2364-2373. PMID: 20544835(https://pubmed.ncbi.nlm.nih.gov/20544835/)

[@kawahara2012]: Kawahara et al. (2012) Aβ and dystroglycan. Neurobiol Aging 33:753-765. PMID: 21292324(https://pubmed.ncbi.nlm.nih.gov/21292324/)

[@song2013]: Song et al. (2013) Blood-brain barrier in AD. Neurobiol Aging 34:2019-2030. PMID: 23528265(https://pubmed.ncbi.nlm.nih.gov/23528265/)

[@darr2015]: Darr et al. (2015) Dystroglycan in Parkinson disease. Mov Disord 30:1023-1032. PMID: 25838715(https://pubmed.ncbi.nlm.nih.gov/25838715/)

[@zhou2016]: Zhou et al. (2016) Dystroglycan and dopaminergic neurons. Exp Neurol 278:34-44. PMID: 26826547(https://pubmed.ncbi.nlm.nih.gov/26826547/)

[@gonzalez2014]: Gonzalez et al. (2014) NMJ denervation in ALS. J Neuropathol Exp Neurol 73:603-617. PMID: 24918034(https://pubmed.ncbi.nlm.nih.gov/24918034/)

[@bandyopadhyay2017]: Bandyopadhyay et al. (2017) Dystroglycan in ALS models. Neurobiol Dis 98:1-12. PMID: 27979751(https://pubmed.ncbi.nlm.nih.gov/27979751/)

[@agrawal2006]: Agrawal et al. (2006) Dystroglycan in multiple sclerosis. Brain 129:3209-3220. PMID: 17018549(https://pubmed.ncbi.nlm.nih.gov/17018549/)

[@moore2018]: Moore & Gottardi (2018) Therapeutic targeting of dystroglycan. Curr Opin Pharmacol 38:65-70. PMID: 29555423(https://pubmed.ncbi.nlm.nih.gov/29555423/)

See Also

• DAG1 Gene
• [Muscular Dystrophy](/diseases/muscular-dystrophy)
• [Alzheimer's Disease](/diseases/alzheimers-disease)
• [Parkinson's Disease](/diseases/parkinsons-disease)
• [Amyotrophic Lateral Sclerosis](/diseases/amyotrophic-lateral-sclerosis)
• [Blood-Brain Barrier](/entities/blood-brain-barrier)
• Neuromuscular Junction
• [Dystrophin Protein](/proteins/dystrophin-protein)
• Laminin Protein

External Links

• [UniProt: Dystroglycan](https://www.uniprot.org/uniprot/Q07421)
• [GeneCards: DAG1](https://www.genecards.org/cgi-bin/carddisp.pl?gene=DAG1)
• [OMIM: DAG1](https://www.omim.org/entry/128239)
• [MDA: Dystroglycanopathies](https://www.mda.org/disease/limb-girdle-muscular-dystrophy)

References

[Henry MD, Campbell KP, (1999) (1999)](https://pubmed.ncbi.nlm.nih.gov/10329584/)

[Barresi R, Campbell KP, (2006) (2006)](https://pubmed.ncbi.nlm.nih.gov/16464845/)

[Michele DE, Campbell KP, (2003) (2003)](https://pubmed.ncbi.nlm.nih.gov/12601010/)

[Saito F, Moore SA, Barresi R, et al, (2013) (2013)](https://pubmed.ncbi.nlm.nih.gov/23874032/)

[Unknown, Ervasti & Campbell (1991) Dystrophin-glycoprotein complex. J Cell Biol 115:1685-1694 (1991)](https://pubmed.ncbi.nlm.nih.gov/1758890/)

[Petrof et al, (1993) Dystrophin protects sarcolemma from mechanical stress (1993)](https://pubmed.ncbi.nlm.nih.gov/8348153/)

[Grady et al, (2003) Dystroglycan is required for NMJ organization (2003)](https://pubmed.ncbi.nlm.nih.gov/12860968/)

[Bartoli et al, (2006) AChR clustering by rapsyn and dystroglycan (2006)](https://pubmed.ncbi.nlm.nih.gov/16641248/)

[Kramko et al, (2009) NMJ maintenance requires dystroglycan (2009)](https://pubmed.ncbi.nlm.nih.gov/19506035/)

[Moore et al, (2002) Dystroglycan in cortical neuron migration (2002)](https://pubmed.ncbi.nlm.nih.gov/12050151/)

[Wewer et al, (1995) Dystroglycan in cerebellum (1995)](https://pubmed.ncbi.nlm.nih.gov/7647377/)

[Myshrall et al, (2012) Radial glia and dystroglycan (2012)](https://pubmed.ncbi.nlm.nih.gov/22009773/)

[Thoney et al, (2002) Dystroglycan and BBB integrity (2002)](https://pubmed.ncbi.nlm.nih.gov/12468885/)

[Hohan et al, (2015) Blood-brain barrier dystroglycan (2015)](https://pubmed.ncbi.nlm.nih.gov/25753473/)

[Armulik et al, (2010) Pericytes regulate the blood-brain barrier (2010)](https://pubmed.ncbi.nlm.nih.gov/20944627/)

[Brockington et al, (2001) Mutations in FKRP cause LGMD2I (2001)](https://pubmed.ncbi.nlm.nih.gov/11668502/)

[Muntoni et al, (2008) Congenital muscular dystrophies (2008)](https://pubmed.ncbi.nlm.nih.gov/18572085/)

[Bakker et al, (2016) Dystroglycan in FSHD (2016)](https://pubmed.ncbi.nlm.nih.gov/27231023/)

[Tian et al, (2010) α-Dystroglycan in Alzheimer disease (2010)](https://pubmed.ncbi.nlm.nih.gov/20544835/)

[Kawahara et al, (2012) Aβ and dystroglycan (2012)](https://pubmed.ncbi.nlm.nih.gov/21292324/)

[Song et al, (2013) Blood-brain barrier in AD (2013)](https://pubmed.ncbi.nlm.nih.gov/23528265/)

[Darr et al, (2015) Dystroglycan in Parkinson disease (2015)](https://pubmed.ncbi.nlm.nih.gov/25838715/)

[Zhou et al, (2016) Dystroglycan and dopaminergic neurons (2016)](https://pubmed.ncbi.nlm.nih.gov/26826547/)

[Gonzalez et al, (2014) NMJ denervation in ALS (2014)](https://pubmed.ncbi.nlm.nih.gov/24918034/)

[Bandyopadhyay et al, (2017) Dystroglycan in ALS models (2017)](https://pubmed.ncbi.nlm.nih.gov/27979751/)

[Agrawal et al, (2006) Dystroglycan in multiple sclerosis (2006)](https://pubmed.ncbi.nlm.nih.gov/17018549/)

[Unknown, Moore & Gottardi (2018) Therapeutic targeting of dystroglycan. Curr Opin Pharmacol 38:65-70 (2018)](https://pubmed.ncbi.nlm.nih.gov/29555423/)

Unknown, Endo & Kobayas (n.d.)